Indoco Remedies has received EU GMP certification for its Goa manufacturing facility from the Malta Medicines Authority, confirming compliance with Good Manufacturing Practice requirements under the EC Directive. The certification follows an inspection of the solid oral dosage form plant (Plant I) conducted from November 19 to November 24, 2025. This approval enables the company to reinforce its commitment to delivering high-quality healthcare products to global markets.

The disclosure was made to the National Stock Exchange of India and Bombay Stock Exchange under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The inspection focused on the company's manufacturing capabilities and quality systems at the Goa unit.

Certification Details

The key details of the EU GMP certification are outlined below:

Management Commentary

Aditi Panandikar, Managing Director of Indoco Remedies, stated that compliance is a core value driving the company's quality systems. She emphasized that the approval reinforces the organization's commitment to delivering the highest quality healthcare to customers worldwide. The company operates 10 manufacturing facilities, including six for finished dosage forms and four for active pharmaceutical ingredients, supported by a research and development centre.

Indoco Remedies Limited has formally intimated the stock exchanges regarding the demise of Dr. Anand Nadkarni (DIN: 06881461), Non-Executive Director of the Company, on Friday, 15th May, 2026. The disclosure was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and was communicated to both the National Stock Exchange of India Limited and the Bombay Stock Exchange Limited.

Regulatory Disclosure Under SEBI Regulation 30

The intimation was filed by Ramanathan Hariharan, Company Secretary & Head Legal of Indoco Remedies, on 15th May, 2026. The filing references SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January, 2026, under which the requisite details of the cessation have been disclosed as Annexure A.

The following details have been provided as required under the applicable regulatory framework:

Company Pays Tribute

Indoco Remedies expressed profound grief over the sudden and unexpected passing of Dr. Anand Nadkarni. The Company noted that his association as a Non-Executive Director had immensely benefitted the organisation, and described his loss as irreparable. All directors and employees of the Company conveyed deep sympathy, sorrow, and condolences to his family.